Benesch Matthew G K, Yang Zelei, Tang Xiaoyun, Meng Guanmin, Brindley David N
Discipline of Surgery, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, A1B 3V6, Canada; Signal Transduction Research Group, Department of Biochemistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, T6G 2S2, Canada.
Signal Transduction Research Group, Department of Biochemistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, T6G 2S2, Canada.
Trends Cancer. 2017 Nov;3(11):748-752. doi: 10.1016/j.trecan.2017.09.004. Epub 2017 Oct 2.
Lysophosphatidate (LPA) is emerging as a potent mediator of cancer progression in the tumor microenvironment. Strategies for targeting LPA signaling have recently entered clinical trials for fibrosis. These therapies have potential to improve the efficacies of existing chemotherapies and radiotherapy by attenuating chronic inflammation, irrespective of diverse mutations within cancer cells.
溶血磷脂酸（LPA）正逐渐成为肿瘤微环境中癌症进展的有力介质。针对LPA信号传导的策略最近已进入纤维化的临床试验。这些疗法有可能通过减轻慢性炎症来提高现有化疗和放疗的疗效，而不考虑癌细胞内的各种突变。
